NASDAQ: PBYI
Puma Biotechnology Inc Stock

$2.86-0.05 (-1.72%)
Updated Feb 14, 2025
PBYI Price
$2.86
Fair Value Price
-$0.16
Market Cap
$140.39M
52 Week Low
$2.23
52 Week High
$7.15
P/E
5.96x
P/B
1.97x
P/S
0.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$243.57M
Earnings
$23.24M
Gross Margin
69.3%
Operating Margin
15.54%
Profit Margin
9.5%
Debt to Equity
2.11
Operating Cash Flow
$34M
Beta
1.08
Next Earnings
Feb 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A

PBYI Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PBYI's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PBYI
Ranked
#5 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important PBYI news, forecast changes, insider trades & much more!

PBYI News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PBYI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PBYI ($2.86) is overvalued by 1,856.4% relative to our estimate of its Fair Value price of -$0.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PBYI ($2.86) is not significantly undervalued (1,856.4%) relative to our estimate of its Fair Value price of -$0.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PBYI is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PBYI due diligence checks available for Premium users.

Valuation

PBYI fair value

Fair Value of PBYI stock based on Discounted Cash Flow (DCF)

Price
$2.86
Fair Value
-$0.16
Undervalued by
1,856.40%
PBYI ($2.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PBYI ($2.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PBYI is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PBYI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
5.96x
Industry
-169.22x
Market
37.92x
PBYI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PBYI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

PBYI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.97x
Industry
4.77x
PBYI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PBYI's financial health

Profit margin

Revenue
$80.5M
Net Income
$20.3M
Profit Margin
25.2%
PBYI's Earnings (EBIT) of $37.85M... subscribe to Premium to read more.
Interest Coverage Financials
PBYI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$220.7M
Liabilities
$149.6M
Debt to equity
2.11
PBYI's short-term assets ($156.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBYI's short-term assets ($156.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBYI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PBYI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$11.0M
Investing
$259.0k
Financing
-$11.2M
PBYI's operating cash flow ($33.77M)... subscribe to Premium to read more.
Debt Coverage Financials

PBYI vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PBYIA$140.39M-1.72%5.96x1.97x
MCRBC$142.22M-0.83%-3.62x5.95x
SGMTF$136.83M-3.41%-1.18x0.80x
SEERC$136.21M0.00%-1.78x0.40x
CHRSC$135.95M+1.72%-39.33x-1.55x

Puma Biotechnology Stock FAQ

What is Puma Biotechnology's quote symbol?

(NASDAQ: PBYI) Puma Biotechnology trades on the NASDAQ under the ticker symbol PBYI. Puma Biotechnology stock quotes can also be displayed as NASDAQ: PBYI.

If you're new to stock investing, here's how to buy Puma Biotechnology stock.

What is the 52 week high and low for Puma Biotechnology (NASDAQ: PBYI)?

(NASDAQ: PBYI) Puma Biotechnology's 52-week high was $7.15, and its 52-week low was $2.23. It is currently -60% from its 52-week high and 28.54% from its 52-week low.

How much is Puma Biotechnology stock worth today?

(NASDAQ: PBYI) Puma Biotechnology currently has 49,087,684 outstanding shares. With Puma Biotechnology stock trading at $2.86 per share, the total value of Puma Biotechnology stock (market capitalization) is $140.39M.

Puma Biotechnology stock was originally listed at a price of $14.00 in Apr 24, 2012. If you had invested in Puma Biotechnology stock at $14.00, your return over the last 12 years would have been -79.57%, for an annualized return of -12.4% (not including any dividends or dividend reinvestments).

How much is Puma Biotechnology's stock price per share?

(NASDAQ: PBYI) Puma Biotechnology stock price per share is $2.86 today (as of Feb 14, 2025).

What is Puma Biotechnology's Market Cap?

(NASDAQ: PBYI) Puma Biotechnology's market cap is $140.39M, as of Feb 17, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Puma Biotechnology's market cap is calculated by multiplying PBYI's current stock price of $2.86 by PBYI's total outstanding shares of 49,087,684.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.